m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00646)
Target Name p53 apoptosis effector related to PMP-22 (PERP)
Synonyms
Keratinocyte-associated protein 1; KCP-1; P53-induced protein PIGPC1; Transmembrane protein THW
    Click to Show/Hide
Gene Name PERP
Chromosomal Location 6q23.3
Family TMEM47 family
Function
Component of intercellular desmosome junctions. Plays a role in stratified epithelial integrity and cell-cell adhesion by promoting desmosome assembly; FUNCTION: Plays a role as an effector in the TP53-dependent apoptotic pathway.
    Click to Show/Hide
Gene ID 64065
Uniprot ID
PERP_HUMAN
HGNC ID
HGNC:17637
Ensembl Gene ID
ENSG00000112378
KEGG ID
hsa:64065
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
PERP can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line mouse embryonic stem cells Mus musculus
Treatment: METTL14-/- ESCs
Control: Wild type ESCs
 GSE145309
Regulation
logFC: 1.56E+00
p-value: 2.67E-25
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary The upregulation of METTL14 leads to the decrease of p53 apoptosis effector related to PMP-22 (PERP) levels via m6A modification, promoting the growth and metastasis of pancreatic cancer; therefore METTL14 is a potential therapeutic target for its treatment.
Target Regulation Down regulation
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
In-vitro Model SW1990 Pancreatic adenocarcinoma Homo sapiens CVCL_1723
PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
Panc 03.27 Pancreatic adenocarcinoma Homo sapiens CVCL_1635
MIA PaCa-2 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0428
Capan-2 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0026
BxPC-3 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0186
AsPC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0152
In-vivo Model For the subcutaneous transplantation model, 100 uL of 1 × 106 cells were injected subcutaneously into the right armpit of BALB/c nude mice. Animal weight and tumor diameter were measured once a week from the time of implantation.For the pancreatic cancer orthotopic implantation model, 200 uL of Panc02-lucifer cells (2 × 107) were injected into the pancreas in mice anesthetized and laparotomized. After 4 weeks, the mice were anesthetized and injected with 150 mg/kg d-luciferin, via the tail vein.For the liver metastasis model, BALB/c nude mice received 2 × 106 cells (in 100 uL DMEM), directly injected into the spleen. Their body weight was measured once a week from the time of implantation.
Pancreatic cancer [ICD-11: 2C10]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary The upregulation of METTL14 leads to the decrease of p53 apoptosis effector related to PMP-22 (PERP) levels via m6A modification, promoting the growth and metastasis of pancreatic cancer; therefore METTL14 is a potential therapeutic target for its treatment.
Responsed Disease Pancreatic cancer [ICD-11: 2C10]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model SW1990 Pancreatic adenocarcinoma Homo sapiens CVCL_1723
PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
Panc 03.27 Pancreatic adenocarcinoma Homo sapiens CVCL_1635
MIA PaCa-2 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0428
Capan-2 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0026
BxPC-3 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0186
AsPC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0152
In-vivo Model For the subcutaneous transplantation model, 100 uL of 1 × 106 cells were injected subcutaneously into the right armpit of BALB/c nude mice. Animal weight and tumor diameter were measured once a week from the time of implantation.For the pancreatic cancer orthotopic implantation model, 200 uL of Panc02-lucifer cells (2 × 107) were injected into the pancreas in mice anesthetized and laparotomized. After 4 weeks, the mice were anesthetized and injected with 150 mg/kg d-luciferin, via the tail vein.For the liver metastasis model, BALB/c nude mice received 2 × 106 cells (in 100 uL DMEM), directly injected into the spleen. Their body weight was measured once a week from the time of implantation.
References
Ref 1 Upregulation of METTL14 mediates the elevation of PERP mRNA N(6) adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020 Aug 25;19(1):130. doi: 10.1186/s12943-020-01249-8.